PHOTON-2 Study Addresses Combination Hepatitis C Pill For HIV+ Patients Interview with:
Prof Jean-Michel Molina
Maladies Infectieuses et Tropicales, Hôpital
Saint-Louis, Paris France

Medical Research: What is the background for this study? What are the main findings?

Prof. Molina: Treatment of co-infected patients is complicated by drug drug interactions with HIV drugs, and the news DAAs are not very potent on HCV G2 and 3 infections.

Medical Research: What should clinicians and patients take away from your report?

Prof. Molina: The simple combination of sofosbuvir plus ribavirin (available as a generic drug) provides potent response rates above 80% for co-infected patients with all genotypes, with limited drug drug interactions with HIV drugs.


Labels: ,